|
rs16754
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Recent works have studied the prognostic significance of WT1 polymorphisms and mutations, highlighting the role of SNP rs16754 as a positive prognostic factor in AML patients.
|
29407184 |
2018 |
|
rs16754
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The genetic variant rs16754 of Wilms tumor gene 1 (WT1) has recently been described as an independent prognostic factor in AML patients.
|
25932444 |
2015 |
|
rs16754
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We were unable to confirm the suggested favorable outcome of SNP rs16754 in de novo AML.
|
23070125 |
2012 |
|
rs16754
|
|
|
0.040 |
GeneticVariation |
BEFREE |
To analyze the prevalence and clinical implications of Wilms' tumor 1 (WT1) single nucleotide polymorphism (SNP) rs16754 in the context of other prognostic markers in pediatric acute myeloid leukemia (AML).
|
21189390 |
2011 |
|
rs147001633
|
|
|
0.030 |
GeneticVariation |
BEFREE |
R882H specific DNA hypermethylation events in AML patients were accompanied by R882H specific mis-regulation of several genes with strong cancer connection, which are potential downstream targets of R882H.
|
31620784 |
2019 |
|
rs147001633
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The DNA methyltransferase DNMT3A R882H mutation is observed in 25% of all AML patients.
|
30185810 |
2018 |
|
rs147001633
|
|
|
0.030 |
GeneticVariation |
BEFREE |
AML cells with the R882H mutation have severely reduced de novo methyltransferase activity and focal hypomethylation at specific CpGs throughout AML cell genomes.
|
24656771 |
2014 |
|
rs77375493
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The JAK2 V617F mutation is frequently found in ET, while it is rare in de novo AML.
|
29979407 |
2018 |
|
rs13181
|
|
|
0.020 |
GeneticVariation |
BEFREE |
XPD Lys751Gln and not Asp312Asn polymorphism was associated with chemotherapy-induced cardiotoxicity and response to induction chemotherapy in newly diagnosed cytogenetically normal AML patients.
|
24284041 |
2014 |
|
rs77375493
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We applied single nucleotide polymorphism arrays (SNP-A) to study karyotypic abnormalities in patients with atypical myeloproliferative syndromes (MPD), including myeloproliferative/myelodysplastic syndrome overlap both positive and negative for the JAK2 V617F mutation and secondary acute myeloid leukemia (AML).
|
18030353 |
2007 |
|
rs13181
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We hypothesized that XPD Lys751Gln polymorphism may play a role in causation of AML in children and, as shown in adults, may affect the outcome of childhood AML therapy.
|
16150943 |
2006 |
|
rs183484
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three SNPs (NME1 rs3760468, NME2 rs3744660, and RRM1 rs183484) were associated with worse OS in AML patients.
|
29631596 |
2018 |
|
rs3744660
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three SNPs (NME1 rs3760468, NME2 rs3744660, and RRM1 rs183484) were associated with worse OS in AML patients.
|
29631596 |
2018 |
|
rs1946518
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We determined polymorphisms of NLRP3 (rs35829419), CARD8 (rs2043211), IL-1β (rs16944), IL-18 (rs1946518) and NF-κB -94 ins/del ATTG in de novo AML patients to find out whether they play roles in the susceptibility and severity of AML.
|
27928589 |
2017 |
|
rs2072671
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The AC and CC genotypes of rs2072671 (79A>C) were significantly correlated with shorter overall survival rates (P=0.03, hazard ratio=1.84) and first complete remission duration (P=0.007, hazard ratio=3.24) compared with the AA genotype in the NK-AML patients.
|
26354033 |
2015 |
|
rs2072671
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The AC and CC genotypes of rs2072671 (79A>C) were significantly correlated with shorter overall survival rates (P=0.03, hazard ratio=1.84) and first complete remission duration (P=0.007, hazard ratio=3.24) compared with the AA genotype in the NK-AML patients.
|
26354033 |
2015 |
|
rs2853669
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We show that rs2853669 CC may be a risk factor for the development of AML that may also be used as a prognostic marker to identify high risk normal karyotype-AML (NK-AML) patients, for treatment guidance.
|
26298771 |
2015 |
|
rs751661633
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The AC and CC genotypes of rs2072671 (79A>C) were significantly correlated with shorter overall survival rates (P=0.03, hazard ratio=1.84) and first complete remission duration (P=0.007, hazard ratio=3.24) compared with the AA genotype in the NK-AML patients.
|
26354033 |
2015 |
|
rs104894230
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Co-transduction of Kras(G12D) and AML1/ETO induces acute monoblastic leukemia.
|
24480914 |
2014 |
|
rs121913529
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Co-transduction of Kras(G12D) and AML1/ETO induces acute monoblastic leukemia.
|
24480914 |
2014 |
|
rs1482518887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Co-transduction of Kras(G12D) and AML1/ETO induces acute monoblastic leukemia.
|
24480914 |
2014 |
|
rs1799793
|
|
|
0.010 |
GeneticVariation |
BEFREE |
XPD Lys751Gln and not Asp312Asn polymorphism was associated with chemotherapy-induced cardiotoxicity and response to induction chemotherapy in newly diagnosed cytogenetically normal AML patients.
|
24284041 |
2014 |
|
rs2032582
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype.
|
25155901 |
2014 |
|
rs727503094
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Co-transduction of Kras(G12D) and AML1/ETO induces acute monoblastic leukemia.
|
24480914 |
2014 |
|
rs778036161
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Co-transduction of Kras(G12D) and AML1/ETO induces acute monoblastic leukemia.
|
24480914 |
2014 |